Remix Therapeutics is a clinical-stage biotechnology company at the forefront of a new era in medicine. By focusing on the modulation of RNA processing, the company is unlocking novel therapeutic pathways to address high unmet medical needs, with a primary focus on oncology. Their proprietary platform enables the discovery of small molecule medicines designed to 'remix' the way cells function, providing new hope for patients worldwide.
Backed by top-tier life sciences investors, Remix fosters a culture of scientific excellence and collaborative innovation. As a recognized 'Top Place to Work' in Boston for 2025, the company offers a dynamic environment where researchers and professionals can push the boundaries of modern science while building a meaningful career in the biopharma industry.